Zentalis Pharmaceuticals (ZNTL)

• Market cap: $99.7M
• 1 day: -2.13%
• 5 days: 2.22%
• 1 month: 4.55%
• 3 months: -13.75%
• 6 months: -7.38%
• Year to date: -54%
• 1 year: -64.52%
• 5 years: -97.55%
• 10 years: -94.05%
• Sector: Healthcare
• Industry: Biotechnology

About: Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Employees: 166